Redx Pharma plc Update on Suspension of Trading (8141I)
22 June 2017 - 4:00PM
UK Regulatory
TIDMREDX
RNS Number : 8141I
Redx Pharma plc
22 June 2017
22 June 2017
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Update on Suspension of Trading
Redx, the drug discovery and development company, is today
providing an update on developments since the announcement of the
suspension of its shares from trading on the AIM market of the
London Stock Exchange and the appointment of Jason Baker and Miles
Needham of FRP Advisory LLP as joint administrators (the "Joint
Administrators") on 24 May 2017.
The Joint Administrators are working with the Company's advisers
on proposals to rescue Redx and return the Company to the control
of its directors, with the intention of lifting the suspension and
restoring trading in the ordinary shares.
Discussions regarding these proposals are at a relatively early
stage and there can be no guarantee that these will be concluded
successfully in the short term.
A further announcement will be made in due course, as and when
appropriate.
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators: T: + 44 203
James Rossiter (Morgan Rossiter) 195 3240
Cantor Fitzgerald Europe (Nomad & T: +44 20
Broker) 7894 7000
Phil Davies/ Michael Reynolds
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDDBGDLCGDBGRB
(END) Dow Jones Newswires
June 22, 2017 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024